Cargando…
The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhur Cure M et al.
Autores principales: | Piantoni, Silvia, Colombo, Enrico, Airò, Paolo, Tincani, Angela, Brucato, Antonio, Franceschini, Franco, Andreoli, Laura, Furloni, Roberto, Scarsi, Mirko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305483/ https://www.ncbi.nlm.nih.gov/pubmed/32564213 http://dx.doi.org/10.1007/s10067-020-05232-y |
Ejemplares similares
-
Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome
por: Scarsi, Mirko, et al.
Publicado: (2020) -
Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Response to Belimumab after Twelve Months of Therapy
por: Piantoni, Silvia, et al.
Publicado: (2021) -
Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab
por: Regola, Francesca, et al.
Publicado: (2019) -
Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system
por: Lazzaroni, Maria Grazia, et al.
Publicado: (2021) -
Reduced T-cell repertoire restrictions in abatacept-treated rheumatoid arthritis patients
por: Imberti, Luisa, et al.
Publicado: (2015)